Keyphrases
Neuroblastoma
100%
Facioscapulohumeral muscular Dystrophy
79%
SMCHD1
60%
D4Z4
56%
FSHD2
45%
DUX4
43%
Cyclin-dependent Kinase 4 (CDK4)
31%
Therapeutic Target
31%
D4Z4 Repeats
30%
Aberrations
27%
DNA Methyltransferase 3B (DNMT3B)
23%
FSHD1
22%
Exon Deletion
22%
Derepression
21%
ICF Syndrome
19%
Therapeutic Vulnerabilities
18%
CRISPR/Cas9 Genome Editing
18%
Synergistic Effect
18%
Loss Function
18%
Fusion Protein
18%
Mutation Spectrum
17%
Hypomethylation
17%
Epigenetic Repression
17%
Isogenic
16%
Patient Characteristics
15%
Single-domain Antibody
15%
VHH-Fc
15%
OGG1
15%
8-oxoguanine
15%
Repair Pathway
15%
Anti-amyloidogenic
15%
APP Mice
15%
Murine Double Minute 2 (MDM2)
15%
Combined Targeting
15%
Muscle Differentiation
15%
Gene Expression Pattern
15%
Mutational Spectrum
15%
Synergistic Response
15%
Loss Amplification
15%
Dysferlin
15%
18p Deletion Syndrome
15%
Hinge Domain
15%
Hemizygous
15%
Tumor Characteristics
15%
Disease Penetrance
15%
ZBTB24
15%
Microphthalmia
15%
Arhinia
15%
Pediatric Tumors
15%
Penetrance
15%
Biochemistry, Genetics and Molecular Biology
DUX4
62%
Derepression
31%
Penetrance
31%
Alpha Thalassemia/Mental Retardation X-Linked
31%
Missense
23%
Methylation
20%
Genetics
20%
Exon
18%
Epigenetic Repression
17%
CRISPR/Cas9
16%
Chimeric Protein
16%
Genome Editing
15%
Gene Expression
15%
Single-Domain Antibody
15%
Myogenesis
15%
P53
15%
DNA Methyltransferase
15%
Chromosome 11q
15%
Hemizygosity
15%
Gender Bias
15%
Kinase
15%
Phosphotransferase
15%
Clinical Trial
15%
DNMT3B
15%
Blood Brain Barrier
15%
Amyloid Protein
15%
Guanine
15%
Chromosome 4
14%
Repressor
12%
Intron
11%
Plasma Half Life
11%
Somatic Cell
11%
Epigenetics
9%
Wild Type
7%
Skeletal Muscle
7%
N-Terminus
7%
Biodistribution
7%
Pharmacokinetics
7%
P14arf
6%
Transcription Factors
5%
Preclinical Study
5%
High Throughput Screening
5%
Chromosomal Aberration
5%
DNA Repair
5%
Overall Survival
5%
Survival Rate
5%
Patient Registry
5%
Chromosome 18p
5%
Loss of Function Mutation
5%
Missense Mutation
5%
Medicine and Dentistry
Ganglioneuroblastoma
88%
Neoplasm
31%
Pediatrics
31%
Solid Malignant Neoplasm
22%
Biological Marker
18%
Cancer
15%
Lethality
15%
Protein P53
15%
Gene Expression
15%
Checkpoint Kinase 1
15%
Facioscapulohumeral Muscular Dystrophy
15%
Chromosome 11q
15%
Exon
15%
Irinotecan
15%
DNA Damage Response
15%
Intracranial Tumor
15%
Poly ADP Ribose Polymerase
15%
Childhood Cancer
12%
Olaparib
12%
Malignant Neoplasm
11%
Pediatric Cancer
10%
Rhabdomyosarcoma
10%
Medulloblastoma
10%
Cell Line
10%
Ribosome
9%
Disease
9%
Clinical Trial
9%
Biogenesis
7%
Idasanutlin
7%
Abemaciclib
7%
Ganglioglioma
7%
Osteosarcoma
7%
Ewing Sarcoma
7%
DNA Repair
6%
PARP Inhibitor
6%
Recombination Repair
6%
Homologous Recombination
6%
Cell Mutant
6%
Xenograft
6%
CDK4/6 Inhibitor
5%
